Hims vs MEDVi: Which GLP-1 Provider Is Better?
Short answer: Hims scores higher on our rubric, 7.9/10 against 5.7/10. Full reasoning, pricing and the cases where the other one wins are below.
Hims beats MEDVi overall, scoring 7.9/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: Hims is $188 first month, then $298/mo; MEDVi is $179 first month, then $299/mo. Choose Hims for men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership, but should know going in that hims' customer-experience signal is weaker than smaller competitors. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program.
A side-by-side look at Hims and MEDVi to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
Hims
#7 of 54The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy, Ozempic, Foundayo, and Zepbound paths and has since exited compounded semaglutide for new retail patients. The advertised medication floor is $149, but the required Weight Loss Membership adds $39 in month one and $149/month after that, so the all-in floor is $188 initially and $298 ongoing before any product- or dose-specific increase. Its parent still reports offering access to compounded GLP-1 medications on a limited scale (Q2 2026 results, filed with the SEC August 10, 2026). Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026), significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28%, the highest 1-star rate in our table, clustered around subscription/billing complaints.
Visit HimsMEDVi
#46 of 54MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.
Visit MEDVi| Feature | Hims | MEDVi |
|---|---|---|
| Why each one | The only publicly-traded men's telehealth (NYSE: HIMS) with FDA-approved Wegovy via direct Novo Nordisk partnership. Brand-name access plus SEC accountability, but balanced against a 3.0 Trustpilot rating that lags peers. | Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication. |
| Our Score | 7.9/10 | 5.7/10 |
| Headline Price | $188 first month, then $298/mo | $179 first month, then $299/mo |
| Medication Type | Brand | Both |
| Insurance Accepted | No | No |
| Best For | Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership, but should know going in that Hims' customer-experience signal is weaker than smaller competitors | Users who want both oral and injectable compounded options in one telehealth program |
| Watch out for | Pending federal enforcement action. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings, and Hims has not been found liable. | FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication |
| Ranking | #7 | #46 |
| Get started | Visit Hims | Visit MEDVi |
Pros & Cons Compared
Hims
Pros
- +Publicly traded company (NYSE: HIMS), SEC-filed financials, regulatory accountability that private competitors don't have.
- +2026 Novo Nordisk partnership, FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
- +Medication starts at $149/mo for Wegovy pill, Foundayo, and Ozempic pill; Wegovy or Ozempic pens start at $199 and Zepbound at $299. The required membership makes the lowest all-in path $188 in month one and $298/mo ongoing, and exact product or dose can cost more.
- +Polished app and web experience, among the best user interfaces in men's telehealth.
- +8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461), significant real-world adoption.
Cons
- −Pending federal enforcement action. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings, and Hims has not been found liable.
- −Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026), significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
- −28% of Trustpilot reviews are 1-star, the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
- −Hims reviews span ALL their products (ED, hair loss, mental health, weight loss), not just GLP-1. But the rating still applies because most users don't separate experiences by product.
- −'Hims Oral Kit' is NOT a GLP-1, it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Do not confuse its $69 price with the current brand-name GLP-1 menu.
- −The $149 GLP-1 figures are medication-only. A required Weight Loss Membership costs $39 in month one and $149/mo ongoing, so a $149 medication path totals at least $188 initially and $298/mo after that.
- −Cash-pay only, Hims does not bill insurance, so an insured buyer may do better on a copay.
- −Generic high-volume support, large patient base means less personalized attention than smaller competitors.
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping
Cons
- −FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
- −Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
- −The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
- −Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
Hims edges out MEDVi with a score of 7.9/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: Hims is $188 first month, then $298/mo; MEDVi is $179 first month, then $299/mo. MEDVi offers both brand-name and compounded medications, giving you more flexibility.
Read Full Reviews
Related comparisons
More head-to-head comparisons involving Hims and MEDVi.
Not comparing, just asking? Quick answers to the most-asked GLP-1 questions →
- Hims vs Trimi Health$175/mo month-to-month
- Hims vs Henry Medsfrom $199/mo
- Hims vs Ivim Healthfrom $150/mo
- MEDVi vs Breeze Medsfrom $199/mo
- MEDVi vs Tonik Wellnessfrom $149/mo
- MEDVi vs Novifrom $133/mo
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.
Our pick of these two: Hims · 7.9/10